We guide induced pluripotent stem cells (iPSCs) to self-organize into a beating, hollow, spherical chamber, called a Cardioid, mimicking human heart development and physiology.

Our self-organized Cardioids mimic the natural organization of key cardiac cells and maintain a consistent beating pattern. 

We facilitate self-organized heart chamber development in our Cardioids, while maintaining precise control over their cellular composition. This makes them an ideal model for accurate disease modeling and drug discovery.

Our unique Cardioid technology allows us to develop customized models for heart diseases such as drug-induced and genetic cardiomyopathies, myocardial fibrosis, and many more. These tailored models help us drive advanced drug testing and discovery.

Our extensive assays leverage the unique structure and function of our cardiac chambers, and provide precise control of heart disease phenotypes at structural, functional, and molecular levels.

Together, these assays form a comprehensive discovery platform for evaluating new treatments, and can provide critical insights unattainable through conventional methods.

By integrating our highly representative cardiac model with specialized assays at a fully automated, industry-leading 384-well scale, we have created one of the most robust, scalable, and cost effective  platforms for heart-disease drug discovery and candidate testing.

• Cardioid failure rate is below 3%,
• Structural and functional variability 6-14%
• Automated data analysis pipeline
• Scale up to 50,000 Cardioids per month.

Together, our unique human organoid biology, cutting-edge hardware and AI-supported software forms the foundation of the next generation platform for cardiac drug discovery.